Standout Papers

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced ... 2019 2026 2021 2023 255
  1. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial (2019)
    Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology
  2. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer (2021)
    Jie Wang, Shun Lü et al. JAMA Oncology
  3. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis (2021)
    Xiaoxiang Zhou, Zhuoran Yao et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 13 from Science/Nature 80 standout
Sub-graph 1 of 19

Citing Papers

The present and future of bispecific antibodies for cancer therapy
2024 Standout
Gut microbiota carcinogen metabolism causes distal tissue tumours
2024 StandoutNature
5 intermediate papers

Works of Jie Wang being referenced

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
2021
Interplay between the lung microbiome and lung cancer
2017
and 4 more

Author Peers

Author Last Decade Papers Cites
Jie Wang 3610 2778 1815 340 6.3k
Gérard Zalcman 3360 2963 2108 289 6.5k
You Lü 2784 2579 2620 259 6.9k
Jianying Zhou 2813 2887 2285 368 7.2k
Konstantinos N. Syrigos 2624 1625 1992 195 5.6k
Claire F. Verschraegen 2909 1491 1920 264 6.7k
Yong Song 2807 2835 3431 360 9.5k
Helmut Popper 2700 3519 2039 214 7.0k
Yong He 2916 3463 2335 245 6.6k
Atsushi Mizokami 2358 3293 3303 380 8.5k
Xuefei Li 2962 2685 1833 177 5.6k

All Works

Loading papers...

Rankless by CCL
2026